Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the<scp>NURTURE</scp>studyThomas O. Crawford, Kathryn J. Swoboda, Darryl C. De Vivo et al.|Muscle & Nerve|2023Cited by 117
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O. Crawford, Barbara Steinborn, Nancy L. Kuntz et al.|The Lancet Neurology|2025Cited by 22